Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8852113 | 0.89 | NOS3 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12478430 | 0.85 | — | — | |
| SCHEMBL12478238 | 0.83 | PRMT1 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8334637 | 0.81 | PRMT1 (0.44) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8852165 | 0.81 | GNAI3 (0.34) | NOS3NOS1NOS2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL5572628 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2GNAI3GNAO1 | |
| SCHEMBL8851141 | 0.79 | SLC6A2 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL2002550 | 0.79 | PRMT1 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13744550 | 0.78 | CARM1 (0.41) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8851762 | 0.77 | SLC6A2 (0.40) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | PRMT3 1786/4885CARM1 2716/4885PRMT6 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.